Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.2% on Disappointing Earnings

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 4.2% on Thursday following a weaker than expected earnings announcement. The stock traded as low as $21.30 and last traded at $21.30. Approximately 910 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 570,514 shares. The stock had previously closed at $22.23.

The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.09).

RXRX has been the subject of a number of research reports. Bank of America began coverage on shares of Recursion Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $31.00 target price for the company. JPMorgan Chase & Co. began coverage on Recursion Pharmaceuticals in a research note on Tuesday. They issued a “neutral” rating and a $32.00 price objective for the company. SVB Leerink began coverage on Recursion Pharmaceuticals in a research note on Tuesday. They issued an “outperform” rating and a $33.00 price objective for the company. KeyCorp began coverage on Recursion Pharmaceuticals in a research note on Tuesday. They issued an “overweight” rating and a $36.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on Recursion Pharmaceuticals in a research note on Tuesday. They issued a “neutral” rating and a $34.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $33.20.

Recursion Pharmaceuticals Company Profile (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development.

Recommended Story: Short Selling – Explanation For Shorting Stocks

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.